摩根大通日前确认,对戴恩治疗公司(DYN)维持中性评级立场不变,彰显其对生物技术板块的审慎评估。投资者可通过分析师评级页面获取详尽信息,以把握潜在市场动向。此更新发布于2025年7月15日。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.